Company Overview of The Wistar Institute
The Wistar Institute is an educational institution.
3601 Spruce Street
Philadelphia, PA 19104
Key Executives for The Wistar Institute
President and Chief Executive Officer
Director of Communications
Chief Scientific Officer and Director of Cancer Center
Compensation as of Fiscal Year 2015.
The Wistar Institute Key Developments
The Wistar Institute Presents at IMPACT 2015 Capital Conference, Nov-04-2015 03:30 PM
Oct 21 15
The Wistar Institute Presents at IMPACT 2015 Capital Conference, Nov-04-2015 03:30 PM. Venue: The Ritz-Carlton Hotel, Philadelphia, Pennsylvania, United States. Speakers: Heather Steinman, VP for BD and Executive Director, Technology Transfer.
The Wistar Institute and OncoCyte Corporation Expand Collaboration to Develop Lung Cancer Diagnostic Test
Sep 4 15
The Wistar Institute and OncoCyte Corporation have expanded their collaboration to develop a non-invasive, blood-based test designed to aid physicians in the early detection of lung cancer. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to develop and test potential lung cancer biomarkers identified by Dr. Louise Showe, Ph.D., professor in Wistar's Molecular and Cellular Oncogenesis Program. Under the new expanded agreement, OncoCyte and Wistar will continue their collaboration with the goal of developing a highly sensitive and specific diagnostic test for the early detection of lung cancer. Critical to the success of the next phase of the R&D program will be the analysis of an expanded patient sample set, the transition of sample analysis to a platform capable of commercial scale operations, confirmation of mRNA and miRNA expression, and completion of diagnostic test verification activities. Dependent on achieving successful scientific and technical results at this stage of development, OncoCyte and Wistar will proceed to final validation of the test with the goal of completing that work in 2016 to enable OncoCyte to commercially launch the lung diagnostic test. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research and expects to finalize definitive license agreements with Wistar in the near future.
Anixa Enters into Collaborative Research Agreement with Wistar Institute
Jul 22 15
Anixa Diagnostics Corporation, a wholly owned subsidiary of ITUS Corporation, has entered into a collaborative research agreement with The Wistar Institute to further the development of a cancer screening test. Current methods to identify and measure this biomarker are cumbersome, expensive and unreliable. Anixa has identified alternative methodologies for identifying the biomarker, and through its collaboration with Wistar, expects to refine and corroborate these methodologies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries